ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)

Authors:
Top Cited Papers
Open Access
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • F Hoffmann-La Roche Ltd

This publication has 15 references indexed in Scilit: